SEC Form 4 · accession 0001209191-16-090189
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Lawrence J. Hineline
Officer — VP of Finance CFO
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 8:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $53.63 | Jan 4, 2016 | A | 39,307 | A | Jan 4, 2017 | Jan 4, 2026 | Common Stock | 39,307 | 39,307 | D |
| Restricted Stock UnitF2,F3 | — | Jan 4, 2016 | A | 9,323 | A | Jan 4, 2017 | — | Common Stock | 9,323 | 9,323 | D |
Explanation of responses
- F1The Stock Option vests as to one third of the shares on January 4, 2017, one third of the shares on January 4, 2018 and one third of the shares on January 4, 2019.
- F2Each Restricted Stock Unit represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Intra-Cellular Therapies, Inc.
- F3The Restricted Stock Units vest as to one third of the shares on January 4, 2016, one third of the shares on January 4, 2017 and one third of the shares on January 4, 2018, subject to the reporting person's continuous service with Intra-Cellular Therapies, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within three days of each such vesting date.